Product Information

DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Major Pharmaceuticals, priced at $0.8961 per EA under NDC 00904725468. Its NADAC has been published 56 times since Oct 22, 2025.

FDA first approved this application on Mar 11, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The Low Outlier badge above means this manufacturer's average price in the Dabigatran Etexilate market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

DABIGATRAN ETEXILATE 110 MG CP

Dabigatran Etexilate
$0.8961per EA
Low Outlier

Strength

110 mg/1

NDC

00904725468

Classification

Generic

Dosage Form

CAPSULE, COATED PELLETS

Route

ORAL

Effective Date

10/21/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208040

FDA Approved

3/11/2020

TE Code

AB

On Market Since

6/23/2025

Pharmacological Classes

Direct Thrombin Inhibitor
Thrombin Inhibitors

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 56 times since Oct 22, 2025, and over the history we have for it it has declined 47.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.8961 per EA
All-time high$1.7206 (Nov 12, 2025)
All-time low$0.8961 (Oct 21, 2026)
52-week high$1.6053
52-week low$0.8961
Median price$0.9737
Average price$1.1233
Largest weekly change-12.4% (Dec 17, 2025)
Weeks tracked56
Tracking sinceOct 22, 2025

Price History

1W

0.0%

1M

-4.4%

3M

-8.0%

6M

-2.8%

1Y

-47.9%

3Y

N/A

5Y

N/A

All

-47.9%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?

The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Major Pharmaceuticals, is $0.8961 per EA (NDC 00904725468), effective Nov 11, 2026.

How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?

Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 47.9%. It has been tracked across 56 weekly CMS publications since Oct 22, 2025.

What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?

Since Oct 22, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.8961 (Oct 21, 2026) to a high of $1.7206 (Nov 12, 2025), with a median of $0.9737 per EA.

Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?

3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, but none are currently priced below it.

Who manufactures DABIGATRAN ETEXILATE 110 MG CP?

DABIGATRAN ETEXILATE 110 MG CP (NDC 00904725468) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.